Neion Bio is a New York biotech company that genetically engineers chicken eggs into factories for complex biologic drugs. Its Raptor platform aims to make monoclonal antibodies and other glycosylated proteins at a fraction of the capital cost and carbon footprint of conventional cell-culture bioreactors. Founded in 2024 and emerged from stealth in March 2026, the company raised an oversubscribed $23 million Series A in June 2026 and signed an early multi-product biosimilar deal with a major global pharmaceutical company.
Pleno Inc. is a San Diego multi-omic instrument company rebuilding the economics of biological target detection. Its RAPTOR platform, powered by proprietary Hypercoding technology borrowed from telecommunications signal processing, can detect up to 10,000 targets in a single sample at PCR-like speed and cost. Founded by serial entrepreneur Pieter van Rooyen, the company is moving from R&D into commercial launch with backing from Deerfield Management and Foresite Capital.